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Available online 17 September 2016Human skin ﬁbroblasts were isolated from a 48-year-old patient carrying compound heterozygous mutations
(c.610+364GNA and c.1311ANG) in OPA1, responsible for early onset optic atrophy complicated by ataxia and py-
ramidal signs (Behr syndrome; OMIM#210000). Fibroblastswere reprogrammedusing episomal plasmids carrying
hOCT4, hSOX2, hKLF4, hL-MYC and hLIN28. The generated transgene-free line iPS-OPA1-BEHR showed no additional
genomic aberrations, maintained the disease-relevant mutations, expressed important pluripotency markers and
was capable to differentiate into cells of all three germ layers in vitro. The generated iPS-OPA1-BEHR line might
be a useful platform to study the pathomechanism of early onset complicated optic atrophy syndromes.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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In this study ﬁbroblasts were isolated and reprogrammed from a
48-year-old female patient carrying compound heterozygous muta-
tions (c.610+364GNA and c.1311ANG) in OPA1. The combination
of a deep intronic mutation and a mutation in an intragenic modiﬁer
leads to a severe early-onset optic atrophy phenotype complicated
by ataxia and pyramidal signs (Behr syndrome; OMIM #210000)
(Bonifert et al., 2014) (Chao de la Barca et al., 2016). The iPSC line
iPS-OPA1-BEHR was established by nucleofection of episomal plas-
mids carrying the sequence of OCT4, SOX2, KLF4, L-MYC and LIN28
(Okita et al., 2011). To prove genomic integrity upon
reprogramming, whole-genome single nucleotide polymorphism
(SNP) genotyping of original ﬁbroblasts and the generated iPSC line
iPS-OPA1-BEHR was performed (Fig. 1A). Additionally both muta-
tion-sites were resequenced (Fig. 1B) and genomic integration of
episomal plasmids was excluded (Fig. 1C). Pluripotency of generated
iPS-OPA1-BEHR was analysed via alkaline phosphatase staining
(ALP) (Fig. 2A), staining of pluripotency markers OCT4, TRA-1-81
and SSEA-4 (Fig. 2B), comparative qRT-PCR analysis of pluripotency
markers (OCT4, NANOG, KLF4, C-MYC, SOX2, REX1, DNMT3B and
TDGF1) with human embryonic stem cells and ﬁbroblasts (Fig. 2C)
as well as by the capability to differentiate into cells of all three
germ layers (ectoderm, mesoderm, endoderm) (Fig. 2D).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Genomic validation of iPS-OPA1-BEHR. (A) Karyograms of iPSC line iPS-OPA1-BEHR with respective original ﬁbroblast line. Every chromosome with the corresponding B allele
frequency and log R ratio is displayed. (B) Sanger sequencing of patient-speciﬁc mutations. Sequences of iPS-OPA1-BEHR and F-OPA-BEHR show compound heterozygous mutations
(c.610+364GNA and c.1311ANG) in OPA1. (C) Transgene-free state of iPSC line iPS-OPA1-BEHR proven via PCR with DNA from iPS-OPA1-BEHR and plasmid-speciﬁc primer for OCT3/
4, SOX2, KLF4, and L-MYC. Plasmid samples as positive control, and ddH2O as negative control.
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Reprogramming of ﬁbroblast to iPSCs
Fibroblastswere obtained from a skin biopsy of a 48-year-old female
patient carrying compound heterozygous mutations (c.610+364GNA
and c.1311ANG; NM: 130837.1) in OPA1. The patient suffered from
optic atrophy and visual loss since the age of 2 years. At 6 years of age
progressive gait difﬁculties occurred due to cerebellar ataxia, spasticity
and peripheral neuropathy as described in more detail in Bonifert et
al. (2014). Skin tissue was dissected and directly plated in a 25 cm2 tis-
sue culture ﬂask with Dulbecco's modiﬁed eagle's medium (DMEM)
high glucose (Life Technologies) with 10% fetal bovine serum (FBS,
Life Technologies) for 10 days at 37 °C and 5% CO2. Fibroblasts were ex-
panded by medium change every 2–3 days and reprogrammed by elec-
troporation of 1 × 105 cells with a total of 1 μg per episomal plasmid
(pCXLE-hUL, pCXLE-hSK and pCXLE-hOCT4) (Okita et al., 2011). After
electroporation ﬁbroblasts were cultivated for 1 day in ﬁbroblast medi-
um. On day 2 ﬁbroblast growth factor-2 (FGF-2, 2 ng/ml, Peprotech)
was added to the medium followed by medium change to Essential 8
(E8) supplementedwith 100 μMNaB (SigmaAldrich) on day 3.Mediumchange was performed every other day. iPSC colonies were manually
picked approx. 3–4 weeks after electroporation and expanded on
Matrigel-coated dishes in E8 medium. iPSCs were split by adding PBS/
EDTA (0.02% EDTA in PBS) and replated in a ratio of 1:6–1:12. Around
passage 5–10 iPSCs were genomically and functionally analysed and
frozen in E8medium supplementedwith 40% KOSR (Life Technologies),
10% DMSO (Sigma-Aldrich), and 1 μM Y-27632 (Abcam Biochemicals).
SNP array analysis
DNA of iPSCs was isolated with DNeasy Blood and Tissue Kit
(Qiagen) according to manufacturer's instructions. Whole-genome
SNP genotyping was conducted using the Inﬁnium OmniExpressExome-
8 BeadChip (Illumina). Data analysis was performed with Illumina
BeadStudio.
Sequencing of mutation site
DNA from the patient's ﬁbroblasts and iPSCs was extracted using
the DNeasy blood & tissue kit (Qiagen) according to manufacturer's
guidelines. Subsequently, Sanger sequencing of both mutations
Fig. 2. Functional validation of iPS-OPA1-BEHR. (A) Dark-red staining of alkaline phosphatase assay. (B) Pluripotency marker (OCT4, TRA-1-81 and SSEA-4) identiﬁed by
immunocytochemical staining of iPS-OPA1-BEHR. Nuclei are counterstained with DAPI (blue). Scale bar = 50 μm. (C) qRT-PCR of iPS-OPA1-BEHR, ﬁbroblasts and the human
embryonic stem cell lines HuES-H6 and HuES-H9 with the pluripotency genes OCT4, NANOG, KLF4, C-MYC, SOX2, REX1, DNMT3B and TDGF1. Data as triplicates and normalized to the
housekeeping gene GAPDH and the hESCs HuES-H6. (D) iPS-OPA1-BEHR line is able to differentiate into cells of all three germ layers demonstrated by immunocytochemical staining
(ectoderm (β-III-tubulin (TUJ), scale = 100 μm), endoderm (SOX17 and FOXA2, scale bar = 50 μm) and mesoderm (α-smooth-muscle-actin (SMA), scale bar = 50 μm)). Nuclei are
counterstained with DAPI (blue).
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speciﬁc primer sets ﬂanking the mutation sites according to standard
procedures by using 3130xl Genetic Analyzer (Applied Biosystems)
and Staden 2.0.0b10 software (Staden Sourceforge) for visualisation.Table 1
Primers (Okita et al., 2011) used for integration analysis by PCR.
Forward sequence Reverse sequence
KLF4 CCACCTCGCCTTACACATGAAG TAGCGTAAAAGGAGCAACATAG
L-MYC GGCTGAGAAGAGGATGGCTAC TTTGTTTGACAGGAGCGACAAT
OCT3/4 CATTCAAACTGAGGTAAGGG TAGCGTAAAAGGAGCAACATAG
SOX2 TTCACATGTCCCAGCACTACCAG TTTGTTTGACAGGAGCGACAATNon-integration of transgenes
DNA was isolated as described before. Using the GoTaq G2 DNA
Polymerase (Promega) according to manufacturer's instruction as
well as plasmid-speciﬁc primers (see Table 1) genomic integration
of the episomal plasmids (pCXLE-hUL, pCXLE-hSK and pCXLE-
hOCT4) was excluded. Via gel electrophoresis on a 2% agarose gel
with Midori Green and Gene Ruler DNA Ladder PCR products were
analysed.Alkaline phosphatase staining
IPSCs were ﬁxed in 4% paraformaldehyde (PFA) for 1 min and
washed 3 times with PBS after reaching a conﬂuency of approx. 60–
80%. Staining solution (40 μl Naphthol AS-MX phosphate alkaline
Table 2
Primers used for validation of pluripotency genes.
Forward sequence Reverse sequence
c-MYC ATTCTCTGCTCTCCTCGACG CTGTGAGGAGGTTTGCTGTG
DNMT3 ACGACACAGAGGACACACAT AAGCCCTTGATCTTTCCCCA
GAPDH AGGTCGGAGTCAACGGATTT ATCTCGCTCCTGGAAGATGG
KLF4 CCATCTTTCTCCACGTTCGC CGTTGAACTCCTCGGTCTCT
NANOG CAAAGGCAAACAACCCACTT TGCGTCACACCATTGCTATT
OCT4 GGAAGGTATTCAGCCAAACG CTCCAGGTTGCCTCTCACTC
REX1 AACGGGCAAAGACAAGACAC AACTCACCCCTTATGACGCA
SOX2 TGATGGAGACGGAGCTGAAG GCTTGCTGATCTCCGAGTTG
TDGF1 GGTCTGTGCCCCATGACA AGTTCTGGAGTCCTGGAAGC
Table 3
Antibodies used for validation of pluripotency genes and in vitro differentiation potential.
Antibody Dilution Manufacturer
Pluripotency Goat anti-OCT4 1:100 Santa-Cruz
Mouse anti-SSEA4 1:500 Abcam
Mouse anti-TRA-1-81 1:500 Merck-Millipore
In vitro differentiation Rabbit anti-FOXA2 1:300 Merck
Mouse anti-SMA 1:100 Dako
Goat anti-SOX17 1:250 R&D systems
Mouse anti-TUJ 1:1000 Sigma-Aldrich
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was applied for 30 min leading to dark red staining of ALP-positive
iPSC colonies.Immunocytochemical staining
iPSCs as well as differentiated cells were ﬁxed in 4% PFA for 15 min
and washed 3 times with PBS. Subsequently, blocking solution (PBS
supplemented with 1% FBS and 0.1% Triton X-100) was added for
45 min and samples were incubated with primary antibody (see
Table 3) for 1 h at room temperature (RT). After 3 times washing in
PBS secondary antibody (Alexa488 or Alexa568 diluted 1:300 (Life
Technologies)) was applied and incubated for 1 h at RT in the dark. Nu-
clear counterstaining was achieved by adding DAPI (1:10,000) for
15 min at RT. After embedding cells in ProLong Diamond Antifade
Mountant (Life Technologies) images were taken with Axio Imager Z1
with ApoTome (Zeiss).qRT-PCR of pluripotency marker
cDNA generated by using the Transcriptor High Fidelity cDNA Syn-
thesis Kit (Roche) aswell as prior isolated total RNA (High Pure RNA Iso-
lation Kit (Roche)) according to manufacturer's guidelines was used for
qRT-PCR analysis. qRT-PCR was performed as triplicates with Light Cy-
cler 480 SYBR Green I Master (Roche) and primers speciﬁc for
pluripotency genes (see Table 2). Normalization of CT-values was
achieved by using the 2−ΔΔCt method with the human embryonic
stem cell line HuES-H6 as reference and GAPDH as housekeeping gene.In vitro differentiation potential
For proving the ectodermal and mesodermal differentiation poten-
tial iPSCswere detached and resuspended in Embryoid Body (EB)medi-
um (80% DMEM/F12 (Life Technologies), 20% KOSR, 1× NEAA, 1× Pen/
Strep, 2 mM L-Glutamine and 0.1 mM 2-Mercaptoethanol) on
AggreWell 800 plates (Stemcell Technologies) with medium change at
day 2. EBs were collected and plated on 0.1% gelatine-covered wells
(Sigma-Aldrich) at day 4. EB medium was exchanged every other day
and cells were cultivated for additional 2–3 weeks. Endodermal differ-
entiation of iPSCs was achieved by addition of endodermal differentia-
tion medium (RPMI1640 (Merck) supplemented with 1× B27 (Life
Technologies), 0.2% FBS, 2 μM CHIR-99021 (Abcam) and 50 ng/ml
Activin A (Peprotech)) for 5 days. CHIR-99021 was removed from day
2 on and medium was changed every day.
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